Contact : firstname.lastname@example.org
Unité de phase I en oncologie - CIC
Hôpital La Timone – Bâtiment F, 1er étage
264, rue St Pierre, 13885 Marseille CEDEX 05 FRANCE
Oncology – early phase trials – AP-HM
Recently awarded CLIP2* (centre labellisé INCa pour les phases précoces) for adults and children patients, l’Assistance Publique des Hôpitaux de Marseille, supported by all the oncology departments of the institution provide patients with early stage therapeutic innovations beyond high quality standard medical care.
The drug cycle
The development of anti-cancer drugs is subject to progressive steps within an ethical and scientific quality standards framework.
The step one, or phase I, is the first administration to patients and contributes to determine, in combination with the tolerance profile study, the dose which will be used.
Then the efficacy is evaluated according to response and survival rates.
A real opportunity for patients
This high level activity has the objective to profit cancer patients an earlier access to innovative therapies.
This perspective represents a real opportunity for all patients, especially for them who failed under previously standards.
Early phase trials include phase I, phase I/II and phase II trials.
The CLIP2 structure is defined, for adults part, according to a model with a main site(located at the Timone Hospital) where phase I and phase I/II trials are conducted and 6 partner sites (Onco-dermatology, hematology, neuro-oncology, digestive oncology, medical oncology and multidisciplinary oncology) where phase II trials are performed in respective pathologies.
Early phase in pediatrics will be still performed in the pediatrics oncology department located at the children hospital due to involvement of specific staff and for practical reasons.
To meet high level requirements of this kind of activity, the phase I unit has qualified and motivated multidisciplinary team included international oncology leaders in their respective pathological area, adequate and certified equipment.
Developement and training to therapeutics innovations
The AP-HM selected for the development of new drugs, is specifically involved in industrial transfert of new target therapies.
In order to develop efficiently this activity, were initiated annual meetings with clinicians, researches, representatives of pharmaceutical companies to debate on topics related to Phase I studies in oncology.
This year, 2017, the selective subject is : « Comment faciliter l’accès des patients aux essais de phase I en Cancérologie »
Access to the 23.06.2017 program (pdf document )
The 2016 session is already scheduled on 06/17/16; the agenda will be coming soon.
Dowload the program (pdf doc)
In 2015 : « Designs pour l'évaluation des nouvelles immunothérapies en phase I »
Access to 06.26.2015 program (pdf document)
In 2014, the topic was: « Essais de phases I en oncologie : Quels designs pour demain ? »
Access to 06.20.2014 program (pdf document)
In 2013, the selected subject was: « Essais de phase I bio-guidés en oncologie: facteur de succès rapide ou risque potentiel d'abandon précoce pour les nouvelles drogues ? »
Access to 06.14.2013 program (pdf document)
In 2012, was taken place the 1st session on « Phases I en oncologie »
Access to 06.29.2012 program (pdf document)
*centre labellisé INCa de phases précoces
CEPCM newsletter juin 2016 (document PDF)
CEPCM newsletter september 2015 (document PDF)
AP-HM CancerO (video web series)
Cancer treatment to each patient's ("C la Santé" talk show, 26 min, french, 02/2013)
CLIP² : Center of early phase cancer trials of Marseille